Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

NCT06765109 is registered in ClinicalTrials.gov with Nuvalent Inc. as lead sponsor.

NCT NCT06765109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06765109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
Lead sponsor
Nuvalent Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 17, 2025
Completion date
December 31, 2029
Enrollment
450 (estimated)
Sites
159

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic lymphoma kinase-positive, non-small cell lung cancer